PTCT PTC Therapeutics, Inc. - Common Stock
$72,62
Kurs · Aug 19, 2026
Fundamentaldaten per Jul 30, 2026
52W-Spanne
$48–$91
57% of range
Analystenbewertung
BUY
21 analysts
Kursziel
$98
+35% upside
P/E (TTM)
9.3
ROE
-331.5%
Nettogewinnmarge
39.4%
Über PTC Therapeutics, Inc. - Common Stock Unternehmensübersicht von Wikipedia
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Mehr lesen
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
PTCT Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$72.62
Marktkapitalisierung
$5.92B
P/E (TTM)
9.3
EPS (TTM)
$7.78
Umsatz (TTM)
$1.73B
Dividendenrendite
—
ROE
-331.5%
Verschuldungsgrad
-1.4
52W-Spanne
$48 – $91
PTCT Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$1.73B
2016-12-31
→
2025-12-31
EPS
$7.78
2019-12-31
→
2025-12-31
Freier Cashflow
$702M
2016-12-31
→
2025-12-31
Margen
39.4%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
PTCT
Peer-Median
P/E (TTM)
9.3
37.2
P/S (TTM) (K/V (TTM))
3.4
9.9
P/B (K/B)
-28.8
8.3
EV / EBITDA
4.7
—
Price / FCF (Kurs / FCF)
8.4
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
PTCT
Peer-Median
Operating Margin (Betriebsgewinnmarge)
50.1%
—
Net Profit Margin (Nettogewinnmarge)
39.4%
-15.1%
ROA
29.7%
-23.3%
ROE
-331.5%
-30.6%
ROIC
1044.7%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
PTCT
Peer-Median
Debt / Equity (Fremdkapital / Eigenkapital)
-1.4
—
Current Ratio (Liquiditätsgrad)
2.3
6.3
Quick Ratio
2.2
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
PTCT
Peer-Median
Revenue YoY (Umsatz YoY)
114.5%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
35.3%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
35.4%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
PTCT
Peer-Median
PTCT Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
21 Analysten
- Starker Kauf 6 28,6%
- Kauf 11 52,4%
- Halten 3 14,3%
- Verkauf 1 4,8%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
14 Analysten · 2026-08-13
Median
$98.00
Jetzt
$72.62
Tief
$70.00
Hoch
$130.00
Median-Ziel
$98.00
+34,9%
Mittelwert-Ziel
$97.86
+34,8%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
1.9%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $0.92 | $0.43 | 0.49% |
| 31. März 2026 | $-0.03 | $-0.48 | 0.45% |
| 31. Dezember 2025 | $-1.67 | $0.04 | -1.7% |
| 30. September 2025 | $0.20 | $-1.40 | 1.6% |
| 30. Juni 2025 | $-0.83 | $-1.08 | 0.25% |
| 31. März 2025 | $10.04 | $-0.22 | 10.3% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | — |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | — |
| COGT | $5.72B | -16.4 | — | — | -83.1% | — |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | — |
| ERAS | $1.06B | -8.5 | — | — | -35.7% | — |
| CAI | $7.62B | -8.4 | 97.0% | -8.4% | -13.2% | — |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | — |
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | — |
| DYN | $3.23B | -5.6 | — | — | -57.8% | — |
| PBLS | — | — | — | — | — | — |
| CELC | $4.81B | -26.3 | — | — | -244.3% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 15
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
Bilanz 27
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
Cashflow 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
Liquidität & Solvenz 4
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 13
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
Gewinn- und Verlustrechnung 14
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | -155,203,905 | 78,471,119 | 78,151,240 | 78,115,836 | -153,301,665 | 76,925,523 | 76,725,070 | 76,496,127 | -148,999,422 | 75,377,997 | 74,730,433 | 73,729,284 | -142,514,082 | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | -163,341,037 | 87,115,369 | 78,151,240 | 86,385,922 | -153,301,665 | 76,925,523 | 76,725,070 | 76,496,127 | -148,999,422 | 75,377,997 | 74,730,433 | 73,729,284 | -142,514,082 | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
Bilanz 27
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
Cashflow 13
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
Liquidität & Solvenz 4
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
Effizienz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
Bewertung (TTM) 13
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.02B | $1.84B | · | $1.76B | $1.74B | $1.77B | · | $790M | $807M | $841M | · | $848M | $817M | $752M | · | $670M | |
| Net Income TTM | $32M | $815M | · | $711M | $596M | $569M | · | $-430M | $-523M | $-562M | · | $-580M | $-599M | $-527M | · | $-522M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | 313.7 | 7.3 | · | 7.7 | 7.5 | 8.3 | · | -6.6 | -4.4 | -3.9 | · | -2.9 | -5.0 | -6.6 | · | -6.8 | |
| P/S | 6.6 | 3.1 | · | 2.8 | 2.2 | 2.3 | · | 3.6 | 2.9 | 2.7 | · | 2.0 | 3.8 | 4.8 | · | 5.4 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| P / FCF | · | -93.7 | · | · | · | 4.6 | · | · | · | 36.5 | · | · | · | -90.2 | · | · | |
| EV / EBITDA | 34.6 | 66.9 | · | 1161.8 | -62.2 | 2.3 | · | -39.0 | -38.4 | 163.9 | · | -16.7 | -15.7 | -51.8 | · | -52.8 | |
| EV / FCF | · | -67.1 | · | · | · | 2.6 | · | · | · | 26.6 | · | · | · | -97.4 | · | · | |
| EV / Revenue | 5.0 | 2.2 | · | 2.0 | 1.3 | 1.3 | · | 2.7 | 1.9 | 1.9 | · | 2.3 | 4.0 | 5.1 | · | 5.4 | |
| Earnings Yield | 0.32% | 13.8% | · | 13.1% | 13.4% | 12.1% | · | -15.2% | -22.6% | -25.8% | · | -34.9% | -20.2% | -15.1% | · | -14.6% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $1.73B | $807M | $938M | $699M | $539M |
| Betriebsgewinnmarge % | 50.1% | -37.5% | -46.9% | — | -69.5% |
| Nettoergebnis | $683M | $-363M | $-627M | $-559M | $-524M |
| Verwässerte EPS | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | -1.4 | -0.3 | -0.3 | — | 300.0 |
| Liquiditätsgrad | 2.3 | 2.4 | 2.0 | — | 1.9 |
| Quick Ratio | 2.2 | 2.2 | 1.7 | — | 1.7 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $702M | $-114M | $-187M | — | $-280M |
Handelssignale Aktuelle Kauf-/Verkaufssignale mit Einstiegspreis und Risiko-Ertrags-Verhältnis
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 403 Einreicher · $5.4B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 83 (+22 vs. Vorquartal) | 43 (-9 vs. Vorquartal) | 133 (-4 vs. Vorquartal) | 109 (+6 vs. Vorquartal) | +2.1M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | $631.875.072 | 7.746.415 | 11,70% | Aktien |
| JANUS HENDERSON GROUP PLC | $479.178.655 | 7.034.622 | 8,87% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401.986.014 | 4.928.111 | 7,45% | Aktien |
| STATE STREET CORP | $375.136.515 | 4.598.952 | 6,95% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $305.000.589 | 3.739.127 | 5,65% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $292.435.873 | 3.585.091 | 5,42% | Aktien |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159.563.645 | 1.956.156 | 2,96% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $155.132.041 | 1.901.417 | 2,87% | Aktien |
| Hood River Capital Management LLC | $141.818.662 | 1.738.613 | 2,63% | Aktien |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140.519.660 | 1.722.688 | 2,60% | Aktien |
| TANG CAPITAL MANAGEMENT LLC | $122.355.000 | 1.500.000 | 2,27% | Aktien |
| Driehaus Capital Management LLC | $117.469.528 | 1.440.107 | 2,18% | Aktien |
| Jefferies Financial Group Inc. | $110.693.916 | 1.357.042 | 2,05% | Aktien |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94.361.749 | 1.156.819 | 1,75% | Aktien |
| Pictet Asset Management Holding SA | $93.629.635 | 1.147.844 | 1,73% | Aktien |
| ARMISTICE CAPITAL, LLC | $87.393.690 | 1.071.395 | 1,62% | Aktien |
| Blue Sparrow, LLC /DE | $85.705.599 | 1.050.700 | 1,59% | Aktien |
| D. E. Shaw & Co., Inc. | $77.478.857 | 949.845 | 1,44% | Aktien |
| Palo Alto Investors LP | $74.950.268 | 918.846 | 1,39% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64.449.436 | 790.112 | 1,19% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $59.015.895 | 723.500 | 1,09% | Aktien |
| Boston Partners | $57.080.953 | 699.871 | 1,06% | Aktien |
| FMR LLC | $56.956.987 | 698.259 | 1,05% | Aktien |
| BANK OF AMERICA CORP /DE/ | $56.350.840 | 690.828 | 1,04% | Aktien |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53.377.940 | 654.382 | 0,99% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $51.486.821 | 631.199 | 0,95% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $47.953.943 | 587.887 | 0,89% | Aktien |
| Ensign Peak Advisors, Inc | $41.442.128 | 508.056 | 0,77% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $40.866.277 | 500.995 | 0,76% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36.050.432 | 441.957 | 0,67% | Aktien |
| Parkman Healthcare Partners LLC | $35.539.315 | 435.691 | 0,66% | Aktien |
| LOOMIS SAYLES & CO L P | $35.387.921 | 433.835 | 0,66% | Aktien |
| Defilade Capital Management, L.P. | $35.376.827 | 433.699 | 0,66% | Aktien |
| GOLDMAN SACHS GROUP INC | $34.153.522 | 418.702 | 0,63% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $32.274.149 | 395.662 | 0,60% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $30.892.190 | 378.720 | 0,57% | Aktien |
| Qube Research & Technologies Ltd | $25.398.777 | 311.374 | 0,47% | Aktien |
| ARMISTICE CAPITAL, LLC | $24.471.000 | 300.000 | 0,45% | Kaufoption |
| Public Sector Pension Investment Board | $23.249.326 | 285.023 | 0,43% | Aktien |
| SEGALL BRYANT & HAMILL, LLC | $22.165.424 | 271.735 | 0,41% | Aktien |
| CITADEL ADVISORS LLC | $20.338.011 | 249.332 | 0,38% | Aktien |
| MORGAN STANLEY | $18.990.210 | 232.808 | 0,35% | Aktien |
| Boxer Capital Management, LLC | $16.314.000 | 200.000 | 0,30% | Aktien |
| RHUMBLINE ADVISERS | $15.718.994 | 192.706 | 0,29% | Aktien |
| AMERIPRISE FINANCIAL INC | $13.904.178 | 170.457 | 0,26% | Aktien |
| PRUDENTIAL FINANCIAL INC | $13.746.176 | 168.520 | 0,25% | Aktien |
| BlackRock, Inc. | $13.589.562 | 166.600 | 0,25% | Aktien |
| Rock Springs Capital Management LP | $13.238.648 | 162.298 | 0,25% | Aktien |
| Hudson Bay Capital Management LP | $13.033.091 | 159.778 | 0,24% | Aktien |
| Russell Investments Group, Ltd. | $12.687.724 | 155.544 | 0,23% | Aktien |
| Schonfeld Strategic Advisors LLC | $12.025.457 | 147.425 | 0,22% | Aktien |
| MARSHALL WACE, LLP | $11.724.301 | 143.733 | 0,22% | Aktien |
| Swiss National Bank | $11.539.300 | 141.465 | 0,21% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $11.063.583 | 135.633 | 0,20% | Aktien |
| Legal & General Group Plc | $10.362.979 | 127.044 | 0,19% | Aktien |
| CITIGROUP INC | $9.272.143 | 113.671 | 0,17% | Aktien |
| FIRST TRUST ADVISORS LP | $9.246.285 | 113.354 | 0,17% | Aktien |
| Longaeva Partners L.P. | $9.119.771 | 111.803 | 0,17% | Aktien |
| JUPITER ASSET MANAGEMENT LTD | $8.927.184 | 109.442 | 0,17% | Aktien |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $8.215.404 | 100.716 | 0,15% | Aktien |
| SECTOR GAMMA AS | $8.157.000 | 100.000 | 0,15% | Aktien |
| WCM INVESTMENT MANAGEMENT, LLC | $7.651.184 | 93.799 | 0,14% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $7.256.141 | 88.956 | 0,13% | Aktien |
| VOYA INVESTMENT MANAGEMENT LLC | $7.239.501 | 88.752 | 0,13% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $7.217.488 | 105.937 | 0,13% | Aktien |
| Aquatic Capital Management LLC | $6.808.648 | 83.470 | 0,13% | Aktien |
| XTX Topco Ltd | $6.682.459 | 81.923 | 0,12% | Aktien |
| MOORE CAPITAL MANAGEMENT, LP | $6.165.713 | 75.588 | 0,11% | Aktien |
| PINNACLE ASSOCIATES LTD | $5.745.383 | 70.435 | 0,11% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $5.744.722 | 84.320 | 0,11% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $5.614.300 | 68.828 | 0,10% | Aktien |
| Capricorn Fund Managers Ltd | $5.212.323 | 63.900 | 0,10% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5.000.241 | 61.300 | 0,09% | Kaufoption |
| INTECH INVESTMENT MANAGEMENT LLC | $4.696.882 | 57.581 | 0,09% | Aktien |
| ExodusPoint Capital Management, LP | $4.672.166 | 57.278 | 0,09% | Aktien |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $4.561.884 | 55.926 | 0,08% | Aktien |
| BARCLAYS PLC | $4.169.858 | 51.120 | 0,08% | Aktien |
| ORBIMED ADVISORS LLC | $4.005.087 | 49.100 | 0,07% | Aktien |
| MetLife Investment Management, LLC | $3.932.653 | 48.212 | 0,07% | Aktien |
| Point72 Europe (London) LLP | $3.829.919 | 62.407 | 0,07% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $3.792.516 | 46.494 | 0,07% | Aktien |
| Phocas Financial Corp. | $3.766.087 | 46.170 | 0,07% | Aktien |
| MARTINGALE ASSET MANAGEMENT L P | $3.627.826 | 44.475 | 0,07% | Aktien |
| Quadrature Capital Ltd | $3.589.488 | 44.005 | 0,07% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.531.981 | 43.300 | 0,07% | Verkaufsoption |
| STATE OF WISCONSIN INVESTMENT BOARD | $3.436.299 | 42.127 | 0,06% | Aktien |
| CREDIT AGRICOLE S A | $3.344.370 | 41.000 | 0,06% | Aktien |
| Fisher Asset Management, LLC | $3.322.345 | 40.730 | 0,06% | Aktien |
| HSBC HOLDINGS PLC | $3.200.425 | 38.732 | 0,06% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $3.134.490 | 38.427 | 0,06% | Aktien |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $3.114.179 | 38.178 | 0,06% | Aktien |
| CenterBook Partners LP | $3.082.938 | 37.795 | 0,06% | Aktien |
| Rafferty Asset Management, LLC | $3.069.805 | 37.634 | 0,06% | Aktien |
| FIFTH THIRD BANCORP | $3.044.843 | 37.328 | 0,06% | Aktien |
| BURNEY CO/ | $3.044.192 | 37.320 | 0,06% | Aktien |
| Vanguard Global Advisers, LLC | $3.033.180 | 37.185 | 0,06% | Aktien |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | $3.007.731 | 36.873 | 0,06% | Aktien |
| Louisiana State Employees Retirement System | $2.969.148 | 36.400 | 0,05% | Aktien |
| JANE STREET GROUP, LLC | $2.854.950 | 35.000 | 0,05% | Verkaufsoption |
| CASTLEARK MANAGEMENT LLC | $2.765.223 | 33.900 | 0,05% | Aktien |
Unternehmensinsider 33 Insider · 13 Führungskräfte · 14 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Stuart Walter Peltz | Chief Executive Officer | 1. Februar 2022 S | 38.728 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 14. Juli 2026 S | 83.986 | 0 | 1 | $-280.743 |
| Emily Luisa Hill | Chief Financial Officer | 1. Februar 2022 S | 37.169 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | 9. Mai 2017 M | 37.850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | 15. Januar 2015 M | 39.247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | 10. Februar 2020 M | 6.744 | 0 | 0 | $0 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 9. Juli 2026 M | 60.299 | 0 | 20 | $-9.184.852 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 6. Juli 2026 M | 105.272 | 0 | 12 | $-1.254.986 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 17. Juni 2026 M | 70.199 | 0 | 1 | $-1.487.474 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 10. Juni 2026 S | 73.411 | 0 | 28 | $-7.477.160 |
| Mark Rothera | Chief Commercial Officer | 24. Mai 2017 M | 33.739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | 3. Januar 2017 A | 6.000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | 4. Januar 2016 A | 3.239 | 0 | 0 | $0 |
| Hege Elisabeth Sollie-Zetlmayer | Direktor | 28. Juli 2026 A | 52.526 | 0 | 0 | $0 |
| Mary L. Smith | Direktor | 9. Juli 2026 M | 21.813 | 0 | 2 | $-1.425.060 |
| Stephanie Okey | Direktor | 7. Januar 2022 A | 4.163 | 0 | 0 | $0 |
| Emma Reeve | Direktor | 7. Januar 2022 A | 7.528 | 0 | 0 | $0 |
| Allan Steven Jacobson | Direktor | 7. Januar 2022 A | 8.348 | 0 | 0 | $0 |
| Dawn Svoronos | Direktor | 7. Januar 2022 A | 29.755 | 0 | 0 | $0 |
| Jerome B Zeldis | Direktor | 7. Januar 2022 A | 6.500 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | Direktor | 3. Januar 2017 A | — | 0 | 0 | $0 |
| Adam Koppel | Direktor | 3. Januar 2017 A | 2.333.333 | 0 | 0 | $0 |
| Ronald C Renaud JR | Direktor | 3. Januar 2017 A | — | 0 | 0 | $0 |
| Richard Aldrich | Direktor | 8. Juni 2015 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | Direktor | 16. März 2015 S | 2.242 | 0 | 0 | $0 |
| Axel Bolte | Direktor | 25. Juni 2013 P | 20.000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | 10%-Eigentümer | 17. Dezember 2013 S | 2.441.504 | 0 | 0 | $0 |
| Matthew B. Klein | — | 4. August 2026 S | 383.868 | 0 | 1 | $-705.722 |
| Michael Schmertzler | — | 2. Januar 2026 A | 163.266 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | — | 2. Januar 2026 A | 22.500 | 0 | 1 | $-916.200 |
| David P Southwell | — | 2. Januar 2026 A | 20.850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | — | 28. April 2017 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | — | 25. Juni 2013 C | 2.256.882 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 3 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 Einreichungen | 30. Januar 2015 | — | Erste Einreichung | — | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 Einreichungen | 12. November 2014 | — | Erste Einreichung | — | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | 5. Juli 2013 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 87 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,81% | 4.145 SH | 8. August 2026 | Täglich |
| PSCH · Invesco Exchange-Traded Fund Trust … | 3,08% | 71.992 SH | 8. August 2026 | Täglich |
| PBE · Invesco Exchange-Traded Fund Trust | 2,59% | 128.216 SH | 8. August 2026 | Täglich |
| XSMO · Invesco Exchange-Traded Fund Trust | 1,52% | 642.023 SH | 8. August 2026 | Täglich |
| BBP · ETFis Series Trust I | 1,37% | 12.510 NS | 30. April 2026 | N-PORT |
| SIXS · EXCHANGE TRADED CONCEPTS TRUST | 1,30% | 22.380 NS | 31. Mai 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1,25% | 23.662 SH | 8. August 2026 | Täglich |
| GURU · Global X Funds | 1,03% | 9.268 NS | 30. April 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,93% | 73.928 NS | 30. April 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0,83% | 10.625 NS | 30. April 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,74% | 98.733 SH | 8. August 2026 | Täglich |
| VMAX · Lattice Strategies Trust | 0,72% | 5.120 NS | 30. April 2026 | N-PORT |
| IJT · iShares Trust | 0,66% | 770.376 SH | 8. August 2026 | Täglich |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,51% | 40.257 NS | 30. April 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,49% | 3.490 NS | 31. Mai 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,49% | 40.488 NS | 31. Mai 2026 | N-PORT |
| IBB · iShares Trust | 0,44% | 588.017 SH | 8. August 2026 | Täglich |
| HQGO · Lattice Strategies Trust | 0,43% | 3.203 NS | 30. April 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,41% | 4.514 SH | 8. August 2026 | Täglich |
| OASC · Unified Series Trust | 0,40% | 4.569 NS | 31. Mai 2026 | N-PORT |
| BRNY · EA Series Trust | 0,40% | 34.057 NS | 30. April 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,37% | 290.018 SH | 8. August 2026 | Täglich |
| XJR · iShares Trust | 0,37% | 9.802 SH | 8. August 2026 | Täglich |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,34% | 35.034 NS | 31. Mai 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,34% | 75.795 SH | 8. August 2026 | Täglich |
| ESSC · Strategy Shares | 0,34% | 1.335 NS | 30. April 2026 | N-PORT |
| IJR · iShares Trust | 0,32% | 5.058.562 SH | 8. August 2026 | Täglich |
| IWO · iShares Trust | 0,31% | 641.280 SH | 8. August 2026 | Täglich |
| BIB · ProShares Trust | 0,31% | 3.062 NS | 31. Mai 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0,31% | 11.451 NS | 31. Mai 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,30% | 39.411 NS | 31. Mai 2026 | N-PORT |
| SAA · ProShares Trust | 0,26% | 961 NS | 31. Mai 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,25% | 22.443 NS | 30. April 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 27.276 NS | 30. April 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,23% | 2.877 NS | 30. April 2026 | N-PORT |
| AFSM · First Trust Exchange-Traded Fund VI… | 0,23% | 3.003 NS | 31. Mai 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,20% | 477.030 SH | 8. August 2026 | Täglich |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,20% | 39.967 NS | 30. April 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,19% | 1.099.640 SH | 8. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,18% | 72.691 SH | 8. August 2026 | Täglich |
| IWM · iShares Trust | 0,18% | 2.102.256 SH | 8. August 2026 | Täglich |
| LRGF · iShares Trust | 0,16% | 84.151 SH | 8. August 2026 | Täglich |
| ISCG · iShares Trust | 0,16% | 22.792 SH | 8. August 2026 | Täglich |
| RSSL · Global X Funds | 0,16% | 34.125 NS | 30. April 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 11.071 NS | 30. April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,15% | 3.710 NS | 31. Mai 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,14% | 35.428 SH | 8. August 2026 | Täglich |
| FSMD · FIDELITY COVINGTON TRUST | 0,14% | 49.932 NS | 30. April 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,14% | 5.350 SH | 8. August 2026 | Täglich |
| SMDX · Tidal Trust III | 0,13% | 2.579 NS | 30. April 2026 | N-PORT |